sIgA-Biotic Complexes for Heat-Stable Infant Immune Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current infant formulas lack functional secretory immunoglobulin A (sIgA) due to heat treatment, and there are limited means to prevent or treat viral infections, particularly in the respiratory tract, with existing compositions not indicating the effectiveness of sIgA-biotic complexes in preventing or treating viral infections.
Innovation Solution
A composition comprising sIgA-biotic complexes, where the biotic is a Bifidobacterium or Lactobacillus, is used to promote immune defense against viral infections by inducing a plasmacytoid dendritic cell and regulatory T cell response via the gut-lung axis, optimizing immune protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heat treatment is applied to ensure microbiological safety of infant formulas, then microbial contamination is reduced, but functional sIgA is degraded and lost
Solution Approach 1:
The patent applies low pasteurization temperature (e.g., 63°C for 30 minutes) instead of high-temperature sterilization to preserve sIgA functionality while still ensuring microbiological safety. This parameter change in heat treatment conditions resolves the contradiction between safety and functional integrity.
Solution Approach 2:
The patent performs sIgA complexation with probiotics before heat treatment, creating a protective complex that shields sIgA from degradation. This preliminary action ensures sIgA functionality is maintained through the heat treatment process.
2Reliability
If sIgA is complexed with probiotics to enhance immune protection, then immune defense against viral infections is improved, but the complexity of the composition increases
Solution Approach 1:
The patent merges sIgA with probiotics to form sIgA-biotic complexes, combining two functional components into a single integrated structure. This merging enhances immune protection while simplifying the overall composition by creating a unified functional unit rather than separate components.
3Reliability
If conventional heat treatment is used to ensure safety, then microbial contamination is prevented, but sIgA functionality is lost leaving infants vulnerable to viral infections
Solution Approach 1:
The patent changes the heat treatment parameters from high-temperature sterilization to low-temperature pasteurization, maintaining microbiological safety while preserving sIgA functionality to protect against viral infections.
Solution Approach 2:
The patent performs sIgA-probiotic complexation before heat treatment to create a protective structure that maintains sIgA functionality through the thermal process, thereby preventing viral infection risk while ensuring safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sIgA-biotic complexes enhance immune defense, reducing the risk of concurrent bacterial infections and long-term complications from viral respiratory infections by promoting a context-specific, dose-duration regulated immune response.
Implementation Method 1
specific binding of sIgA to pathogens (Fab mediated) to mediate immune exclusion and pathogen neutralization
Implementation Method 2
sIgA can also bind to commensal bacteria and probiotics (non-specific binding)
Implementation Method 3
sIgA-bacteria complexes may translocate from the maternal gastrointestinal tract to milk via the entero-mammary link
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3A~3C
AI summary
The present invention relates to complexes between secretory immunoglobulin A (sIgA) and biotic including probiotics, their components and/or inanimate preparations of said beneficial bacteria and/or postbiotics to promote controlled immune responses to prevent and/or treat viral infections in a mammal.